DK1187928T3 - Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics - Google Patents

Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics

Info

Publication number
DK1187928T3
DK1187928T3 DK00949236T DK00949236T DK1187928T3 DK 1187928 T3 DK1187928 T3 DK 1187928T3 DK 00949236 T DK00949236 T DK 00949236T DK 00949236 T DK00949236 T DK 00949236T DK 1187928 T3 DK1187928 T3 DK 1187928T3
Authority
DK
Denmark
Prior art keywords
particles
virus
preparation
screening
functional genomics
Prior art date
Application number
DK00949236T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Hunt
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Ag filed Critical Evotec Ag
Application granted granted Critical
Publication of DK1187928T3 publication Critical patent/DK1187928T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
DK00949236T 1999-06-30 2000-06-30 Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics DK1187928T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14126899P 1999-06-30 1999-06-30
EP99112451 1999-06-30
EP00106109 2000-03-21
EP00110363 2000-05-15
PCT/EP2000/006144 WO2001002551A2 (fr) 1999-06-30 2000-06-30 Particules de type viral, preparation et utilisation de ces dernieres, de preference dans le criblage pharmaceutique et la genomique fonctionnelle

Publications (1)

Publication Number Publication Date
DK1187928T3 true DK1187928T3 (da) 2007-10-08

Family

ID=56290037

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00949236T DK1187928T3 (da) 1999-06-30 2000-06-30 Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics

Country Status (7)

Country Link
EP (1) EP1187928B1 (fr)
JP (1) JP2003504014A (fr)
AT (1) ATE362990T1 (fr)
AU (1) AU6267000A (fr)
DE (1) DE60034947T2 (fr)
DK (1) DK1187928T3 (fr)
WO (1) WO2001002551A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763258B2 (en) * 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7622437B2 (en) 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
US7048949B2 (en) 2000-11-20 2006-05-23 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
DE60037263T2 (de) * 2000-12-29 2008-10-09 Evotec Ag Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
US7070978B2 (en) 2001-06-20 2006-07-04 Toudai Tlo, Ltd. Method for expressing and purifying proteins using budded baculovirus
EP1632778A3 (fr) 2001-07-09 2006-03-29 Euroscreen S.A. Ligand naturel du recepteur couple aux proteines g (gpcr) chemr23 et utilisations de ce ligand
JP2003052370A (ja) * 2001-08-16 2003-02-25 Sentan Kagaku Gijutsu Incubation Center:Kk 発芽バキュロウィルスを用いた機能を有する膜型受容体蛋白質の発現法
WO2003038443A2 (fr) * 2001-10-30 2003-05-08 Vertex Pharmaceuticals Incorporated Procedes d'identification d'un compose pouvant se lier a des recepteurs membranaires
JP2003177131A (ja) * 2001-12-11 2003-06-27 Olympus Optical Co Ltd 生物学的な結合親和性を検出する方法
CA2471504C (fr) 2002-01-07 2014-05-20 Euroscreen S.A. Ligand du recepteur gpr43 couple a une proteine g et utilisations de ce ligand
WO2004003143A2 (fr) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Virus et particules pseudovirales pour presentation multiple d'antigenes et de cibles
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2006033679A2 (fr) * 2004-05-25 2006-03-30 Chimeracore, Inc. Systeme d'administration de medicaments a base de nanoparticules a autoassemblage
US8377691B2 (en) * 2006-01-26 2013-02-19 Integral Molecular, Inc. Lipoparticles comprising ion channels, methods of making and using the same
US8067011B2 (en) 2006-04-07 2011-11-29 Chimeros, Inc. Compositions and methods for treating B-cell malignancies
WO2010120874A2 (fr) 2009-04-14 2010-10-21 Chimeros, Inc. Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation
WO2013034666A2 (fr) 2011-09-08 2013-03-14 Chemcom S.A. Nouveau récepteur aux phéromones de spodoptera littoralis (lépidoptère, noctuidae), identification d'un ligand naturel dudit récepteur et utilisations associées
JP2014527072A (ja) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
US10444245B2 (en) 2012-05-24 2019-10-15 Vib Vzw Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins
EP3004157B1 (fr) 2013-05-31 2017-11-01 ChemCom S.A. Récepteurs olfactifs impliqués dans la perception d'acides carboxyliques de sueur et leur utilisation
CN114478773A (zh) 2015-01-09 2022-05-13 阿达尔塔有限公司 Cxcr4结合分子
GB201504859D0 (en) 2015-03-23 2015-05-06 Vib Vzw Viral particle based small molecule-protein interaction trap
EP3445397B1 (fr) * 2016-04-22 2022-11-09 Vaccinex, Inc. Présentation de protéine transmembranaire sur des virions à enveloppe extracellulaire de poxvirus
AU2018379263B2 (en) 2017-12-05 2022-02-24 Chemcom S.A. Olfactory receptor involved in the perception of musk fragrance and the use thereof
WO2020139843A1 (fr) 2018-12-28 2020-07-02 The Board Of Trustee Of The Leland Stanford Junior University Polypeptide noyau de l'hépatite b génétiquement modifié

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788807T2 (de) * 1986-11-01 1994-06-30 British Bio Technology Fusionsproteine und -partikel.
EP1892296A1 (fr) * 1988-09-02 2008-02-27 Dyax Corporation Production et sélection de protéines de liaison diversifiées recombinantes
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
CN1185811A (zh) * 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
WO1996035798A1 (fr) * 1995-05-10 1996-11-14 Introgene B.V. Ameliorations apportees a des vecteurs retroviraux, appropries en particulier pour la therapie genique
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US8349602B1 (en) * 1996-04-19 2013-01-08 Xenogen Corporation Biodetectors targeted to specific ligands
DE69734829D1 (de) * 1996-07-17 2006-01-12 Us Health Infektiöse pseudovirale papillomavirus partikel
AUPO434196A0 (en) * 1996-12-24 1997-01-23 Crown In The Right Of The Queensland Department Of Health, The An improved therapeutic
WO1998049195A1 (fr) * 1997-04-29 1998-11-05 Universiteit Utrecht Particules de type coronavirus utilisees comme outils pour la vaccination et le traitement
US6451527B1 (en) * 1997-08-29 2002-09-17 Selective Genetics, Inc. Methods using genetic package display for selecting internalizing ligands for gene delivery
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
EP1053347B1 (fr) * 1998-01-09 2007-02-28 Phylogica Limited Procede de detection de peptides
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
EP0960942A3 (fr) * 1998-05-20 2000-01-12 Introgene B.V. Délivrance ciblée via un transporteur d'acide aminé
EP0959135A1 (fr) * 1998-05-20 1999-11-24 Introgene B.V. Présentation de protéines virales et délivrance ciblée au récepteur cellulaire
ES2275350T3 (es) * 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.

Also Published As

Publication number Publication date
JP2003504014A (ja) 2003-02-04
DE60034947D1 (de) 2007-07-05
WO2001002551A3 (fr) 2001-11-08
EP1187928B1 (fr) 2007-05-23
ATE362990T1 (de) 2007-06-15
EP1187928A2 (fr) 2002-03-20
DE60034947T2 (de) 2008-01-24
WO2001002551A2 (fr) 2001-01-11
AU6267000A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
DK1187928T3 (da) Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics
WO2002002783A3 (fr) Vecteurs d'expression
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
WO2000073316A3 (fr) Determinants immunologiques de virus
EP2289550A3 (fr) Anticorps à neutralisation d'ultra haute affinité
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
ATE483970T1 (de) Zellen zur entdeckung von medikamenten
FR2800609B1 (fr) Emulsions transparentes ou translucides, leur procede de preparation et leur utilisation en cosmetique
WO2001019405A3 (fr) Nanoparticules magnetiques a effet biochimique, leur procede de production et leur utilisation
BR9807502B1 (pt) compostos orgÂnicos, processo para sua preparaÇço, bem como composiÇço e aplicaÇço dos mesmos.
DE69836388D1 (de) System und verfahren zur zerkleinerung von material
ID24714A (id) Turunan tiazolidindion tersubstitusi, proses pembuatannya dan penggunaan bahan farmasinya
ATE326985T1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
MA26900A1 (fr) Preparations cosmetiques et/ou pharmaceutiques avec un extrait de la plante argania spinosa.
WO2001032935A3 (fr) Microreseaux moleculaires et procedes de production et d'utilisation de ces derniers
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2000044775A3 (fr) Identification d'epitopes de cellules t restreintes au hla et fortement reactives
WO2001066752A3 (fr) Genes specifiques de la reproduction
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
WO1999012945A3 (fr) Derives de glycosylamine hydrophobes, compositions a base de ces derives et procedes d'utilisation
DE60037263D1 (de) Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
CA2385766A1 (fr) Methodes de production de proteines dans des cellules hotes
WO2004043884A3 (fr) Nouveaux reactifs acylants
DE69934399D1 (de) Komplex aus peptid und mhc-peptid auf oberfläche von phagen